Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Di Leo

Showing results (1-10 of 187) with videos related to

Pageof 19
Sort By:
Clinical Breast Cancer|November 19, 2002
The European experience with docetaxel in the treatment of early-stage breast cancerAngelo Di Leo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be provenAngelo Di Leo, Luca Malorni
Clinical Breast Cancer|September 23, 2003
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?Angelo Di Leo, Jorma Isola
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Mortality associated with irinotecan plus bolus fluorouracil/leucovorinHarry Bleiberg, Angelo Di Leo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancerAngelo Di Leo, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dreamAngelo Di Leo, Erica Moretti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Ode to a past emperorAngelo Di Leo, Catherine Oakman
Breast (Edinburgh, Scotland)|March 30, 2016
Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypesChristopher D Hart, Angelo Di Leo
Cancer Treatment Reviews|June 15, 2013
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impactNatalie H Turner, Angelo Di Leo
Nature Reviews. Clinical Oncology|October 27, 2010
Breast cancer assessment tools and optimizing adjuvant therapyCatherine Oakman, Libero Santarpia, Angelo Di Leo
Pageof 19

Showing results (1-10 of 187) with videos related to

Sort By:
Pageof 19
Clinical Breast Cancer|November 19, 2002
The European experience with docetaxel in the treatment of early-stage breast cancerAngelo Di Leo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be provenAngelo Di Leo, Luca Malorni
Clinical Breast Cancer|September 23, 2003
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?Angelo Di Leo, Jorma Isola
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2002
Mortality associated with irinotecan plus bolus fluorouracil/leucovorinHarry Bleiberg, Angelo Di Leo
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2002
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancerAngelo Di Leo, Marc Buyse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2008
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dreamAngelo Di Leo, Erica Moretti
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Ode to a past emperorAngelo Di Leo, Catherine Oakman
Breast (Edinburgh, Scotland)|March 30, 2016
Relative benefits of newer adjuvant chemotherapy regimens in luminal breast cancer subtypesChristopher D Hart, Angelo Di Leo
Cancer Treatment Reviews|June 15, 2013
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impactNatalie H Turner, Angelo Di Leo
Nature Reviews. Clinical Oncology|October 27, 2010
Breast cancer assessment tools and optimizing adjuvant therapyCatherine Oakman, Libero Santarpia, Angelo Di Leo
Pageof 19